Description
Release form
Capsules.
Packing
30 pcs.
Pharmacological action
Lipantil 200 M – a lipid-lowering drug from the group of derivatives of fibroic acid. Lowers triglycerides and (to a lesser extent) blood cholesterol. Helps to reduce the content of VLDL, LDL (to a lesser extent), increase the content of anti-atherogenic HDL. It activates lipoprotein lipase and thereby affects the metabolism of triglycerides, disrupts the synthesis of fatty xylots and cholesterol, and helps to increase the number of LDL receptors in the liver. Fenofibrate reduces platelet aggregation, reduces elevated plasma fibrinogen levels, can slightly lower the blood glucose level in patients with diabetes mellitus, and reduces the level of uric acid in the blood.
Indications
– Hypercholesterolemia (type IIa according to the classification of Fredrickson).
– Endogenous hypertriglyceridemia (type IV according to the classification of Fredrickson).
– Mixed hyperlipidemia (type IIb and III according to the classification of Fredrickson).
Contraindications
– Severe impairment of liver function.
– Severe renal impairment.
– The presence of a history of phototoxic or photoallergic reactions in the treatment of fenofibrates or other drugs similar in structure (ketoprofen).
– Combination with other fibrates.
– Congenital galactosemia.
– Lactase deficiency.
– Children and teens under 18 years of age.
– Pregnancy.
– Lactation (breastfeeding).
Use during pregnancy and lactation
Lipantil 200 M is contraindicated for use during pregnancy and lactation (breastfeeding), due to the lack of sufficient data on the safety of the drug during these periods.
Special instructions
In the absence of effect after 3-6 months of taking the drug, concomitant or alternative therapy can be prescribed.
There are reports of the effects of fibrates on muscle tissue, including rare cases of necrosis. These processes occur more often with a decreased level of plasma albumin. With the development of diffuse myalgia in the patient, an increase in the level of creatine phosphokinase (5 times higher than normal), treatment with Lipantil 200 M should be discontinued.
also the risk of rhabdomyolysis increases while taking the drug with HMG-CoA reductase inhibitors and other fibrates.
Lipantil 200 M contains lactose, therefore it is contraindicated in congenital galactosemia, lactase deficiency, glucose malabsorption syndrome or galactose.
With the combined use of Lipantil 200 M and anticoagulants, more frequent monitoring of prothrombin time is necessary during the selection of a dose of indirect anticoagulant during treatment with fibrates and within 8 days after their withdrawal.
MAO inhibitors should not be prescribed concomitantly with fenofibrate.
With prolonged treatment, monitoring of hepatic transaminase activity every 3 months in the first year of therapy is necessary. In cases of increased activity of the enzymes AST or ALT more than 3 times compared with VGN, the drug is stopped.
Composition of
1 capsule (micronized) 200 mg.
Dosing and Administration
Lipantil 200 M is prescribed 1 caps./day during one of the main meals. The duration of therapy is determined by the attending physician. During therapy, diet is recommended.
Side effects of
From the musculoskeletal system: diffuse myalgia, soreness, weakness rarely – rhabdomyolysis (in some cases, severe enough). When treatment is discontinued, these phenomena are usually reversible.
From the digestive system: dyspepsia, a transient increase in the activity of hepatic transaminases.
Allergic reactions: skin rash, itching, urticaria, photosensitivity. In some cases, after several months of using the drug, photosensitivity reactions may occur in the form of erythema, papules, vesicles, eczematous rashes.
Drug interaction
The simultaneous administration of Lipantil 200 M with other fibrates is contraindicated. the risk of developing rhabdomyolysis increases. For the same reason, Lipantil 200 M is prescribed with caution in combination with HMG-CoA reductase inhibitors.
With the combined use of Lipantil 200 M and indirect anticoagulants, it is possible to increase their effect and increase the risk of bleeding (prothrombin time control is necessary).
Overdose
Symptoms: No specific symptoms noted.
Treatment: Symptomatic therapy is carried out if necessary.
Storage conditions
The product should be stored in a dry place at 15 ° C to 25 ° C.
Active in still
fenofibrate
Pharmacy Conditions
In retseptu
